Table 1
Clinical characteristics of 20 patients.
| CASE | AGE/SEX | DISEASE | AETIOLOGY | CHILD-PUGH CLASSIFICATION | CHEMOTHERAPY BEFORE PVE |
|---|---|---|---|---|---|
| 1 | 71/M | CCA | Normal | B | None |
| 2 | 68/F | HCC | Normal | A | None |
| 3 | 75/F | CCA | Normal | A | None |
| 4 | 60/M | MLC | Normal | A | None |
| 5 | 74/M | HCC | Hepatitis B virus | A | TACE |
| 6 | 60/M | MLC | Normal | A | None |
| 7 | 67/M | CCA | Normal | A | None |
| 8 | 71/M | MLC | Hepatitis B virus | A | None |
| 9 | 72/M | GBC | Normal | A | None |
| 10 | 43/F | MLC | Normal | A | None |
| 11 | 76/M | CCA | Normal | A | None |
| 12 | 50/F | CCA | Normal | A | None |
| 13 | 61/M | HCC | Normal | A | None |
| 14 | 61/M | HCC | Normal | A | None |
| 15 | 65/M | MLC | Normal | A | None |
| 16 | 81/M | CCA | Normal | B | None |
| 17 | 74/M | MLC | Alcoholic hepatitis | A | None |
| 18 | 63/M | CCA | Normal | A | None |
| 19 | 50/F | MLC | Hepatitis C virus | A | None |
| 20 | 50/M | CCA | Normal | B | None |
[i] CCA: cholangiocarcinoma; GBC: gallbladder cancer; HCC: hepatocellular carcinoma; MLC: metastatic liver cancer; TACE: transcatheter arterial chemoembolization: PVE: portal vein embolization.
Figure 1
Scheme depicting the technique of portal vein embolization using sheath injection and balloon occlusion with gelatin sponge.
Figure 2
Portography of a 50-year-old woman with metastatic liver cancer just before portal vein embolization.
Figure 3
Portography shows complete obstruction of the right portal vein after embolization.
Table 2
Liver volume data before and after initial session of PVE-SIBO using GS.
| CASE | CT SCAN AFTER PVE, DAYS | FLR BEFORE PVE, ML | FLR AFTER PVE, ML | FLR/TLV RATIO, % BEFORE PVE | FLR/TLV RATIO, % AFTER PVE | INCREASE RATIO, % | PROCEDURE TIME, MINUTES | CLINICAL OUTCOME |
|---|---|---|---|---|---|---|---|---|
| 1 | 13 | 333 | 450 | 38.2 | 49.8 | 35.1 | ERH | |
| 2 | 11 | 235 | 240 | 18.3 | 20.1 | 2.1 | ERH | |
| 3 | 12 | 274 | 352 | 28.6 | 34.8 | 28.5 | 47 | Inoperable |
| 4 | 12 | 465 | 535 | 29.6 | 33.7 | 15.1 | 61 | ERH |
| 5 | 13 | 484 | 569 | 41.7 | 49 | 17.6 | 74 | ERH |
| 6 | 13 | 502 | 733 | 33.2 | 50.1 | 46.0 | 52 | ERH |
| 7 | 14 | 468 | 684 | 32.1 | 46.7 | 46.1 | 40 | Inoperable |
| 8 | 15 | 329 | 421 | 22.1 | 28.3 | 27.9 | 56 | ERH |
| 9 | 12 | 422 | 618 | 26.1 | 34.3 | 46.4 | 42 | ERH |
| 10 | 14 | 490 | 663 | 34.7 | 47 | 35.3 | 66 | Inoperable |
| 11 | 20 | 436 | 805 | 33.3 | 52.6 | 84.6 | 64 | Inoperable |
| 12 | 12 | 809 | 1079 | 39.6 | 48 | 33.3 | 61 | ERH |
| 13 | 14 | 607 | 654 | 31.3 | 31.8 | 1.5 | 65 | Inoperable |
| 14 | 17 | 293 | 435 | 32.6 | 46.8 | 48.4 | 43 | RH |
| 15 | 20 | 383 | 453 | 31.8 | 38.5 | 18.2 | 55 | RH |
| 16 | 15 | 318 | 450 | 36 | 43.8 | 41.5 | 40 | Inoperable |
| 17 | 13 | 431 | 445 | 41.6 | 45.7 | 3.2 | 60 | RH |
| 18 | 14 | 358 | 438 | 29.5 | 36 | 22.3 | 46 | RH |
| 19 | 14 | 263 | 402 | 27.2 | 38.8 | 52.8 | 32 | ERH |
| 20 | 18 | 370 | 700 | 29 | 51.1 | 89.1 | 45 | ERH |
| Avg. | 14.3 ± 2.57 | 413.5 ± 133.0 | 556.3 ± 190.1 | 31.8 ± 6.0 | 41.3 ± 8.87 | 34.7 ± 23.7 | 52.7 ± 11.4 |
[i] CT: computed tomography; ERH: extended right hepatectomy; FLR: future liver remnant; GS: gelatin sponge; PVE: portal vein embolization; RH: right hepatectomy; SIBO: sheath injection with balloon occlusion; TLV: total liver volume.